PMID- 29702938
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 2212-1102 (Electronic)
IS  - 2212-1099 (Linking)
VI  - 3
DP  - 2014 May
TI  - The Patient-Related Burden of Pegylated-Interferon-alpha Therapy and Adverse Events 
      among Patients with Viral Hepatitis C in Japan.
PG  - 50-58
LID - S2212-1099(14)00003-X [pii]
LID - 10.1016/j.vhri.2014.01.002 [doi]
AB  - OBJECTIVES: Pegylated-interferon-alpha (IFN-alpha)-based therapies for viral hepatitis C 
      (HCV) are effective, but they are associated with several adverse events (AEs). 
      The primary objectives of this study were to quantify the burden of IFN-alpha-based 
      treatment and to measure the prevalence and burden of IFN-alpha-related AEs in Japan. 
      METHODS: A cross-sectional survey was administered online to patients with HCV in 
      2013. Patients who were currently taking IFN-alpha-based therapy (n = 188) were 
      compared with patients who were taking a liver protectant but not IFN-alpha-based 
      therapy (n = 180) and with patients who were untreated (n = 365) on measures of 
      health-related quality of life (using the Hepatitis Quality of Life 
      Questionnaire, version 2), work productivity, and health care resource use, 
      controlling for sociodemographic characteristics and health history. Among 
      patients taking IFN-alpha-based therapy, the prevalence and burden of AEs was 
      examined on the same set of health outcomes as noted above along with treatment 
      satisfaction and adherence. RESULTS: Compared with untreated patients, patients 
      using IFN-alpha reported poorer health-related quality of life (physical component 
      summary score, 50.13 vs. 52.04; mental component summary score, 44.12 vs. 47.97), 
      more overall work impairment (32.73 vs. 25.64), more physician visits in the past 
      6 months (14.51 vs. 8.36), and an increased likelihood of an emergency room visit 
      (odds ratio = 7.25) and hospitalization (odds ratio = 4.05) (all P < 0.05). The 
      mean number of AEs was 6.05 for patients using IFN-alpha. All AEs were associated 
      with poorer health outcomes (particularly the mental component summary score), 
      and most were also associated with lower treatment satisfaction and medication 
      adherence. CONCLUSIONS: A significant patient burden for IFN-alpha treatment itself 
      and various AEs was observed. The results suggest that effective, non-IFN-alpha-based 
      treatments may reduce the societal burden.
CI  - Copyright (c) 2014 International Society for Pharmacoeconomics and Outcomes 
      Research (ISPOR). Published by Elsevier Inc. All rights reserved.
FAU - Kumada, Hiromitsu
AU  - Kumada H
AD  - Department of Hepatology, Toranomon Hospital, Tokyo, Japan.
FAU - daCosta DiBonaventura, Marco
AU  - daCosta DiBonaventura M
AD  - Health Outcomes Practice, Kantar Health, New York, NY, USA. Electronic address: 
      marco.dibonaventura@kantarhealth.com.
FAU - Yuan, Yong
AU  - Yuan Y
AD  - Global Health Economics and Outcomes Research, Bristol-Myers Squibb, 
      Lawrenceville, NJ, USA.
FAU - Kalsekar, Anupama
AU  - Kalsekar A
AD  - Global Health Economics and Outcomes Research, Bristol-Myers Squibb, 
      Lawrenceville, NJ, USA.
FAU - Kopenhafer, Lewis
AU  - Kopenhafer L
AD  - Health Outcomes Practice, Kantar Health, New York, NY, USA.
FAU - Tang, Ann
AU  - Tang A
AD  - Health Economics and Outcomes Research, Bristol-Myers K.K., Tokyo, Japan.
FAU - Victor, Timothy W
AU  - Victor TW
AD  - Health Outcomes Practice, Kantar Health, New York, NY, USA.
FAU - L'Italien, Gilbert
AU  - L'Italien G
AD  - Global Health Economics and Outcomes Research, Bristol-Myers Squibb, 
      Lawrenceville, NJ, USA; Yale University School of Medicine, New Haven, CT, USA.
FAU - Chayama, Kazuaki
AU  - Chayama K
AD  - Department of Gastroenterology and Metabolism, Hiroshima University, Hiroshima, 
      Japan.
FAU - Toyota, Joji
AU  - Toyota J
AD  - Department of Hepatology, Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital, 
      Sapporo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20140421
PL  - United States
TA  - Value Health Reg Issues
JT  - Value in health regional issues
JID - 101592642
OTO - NOTNLM
OT  - adherence
OT  - adverse events
OT  - hepatitis C
OT  - interferon
OT  - quality of life
OT  - resource use
OT  - satisfaction
OT  - work impairment
EDAT- 2014/05/01 00:00
MHDA- 2014/05/01 00:01
CRDT- 2018/04/29 06:00
PHST- 2018/04/29 06:00 [entrez]
PHST- 2014/05/01 00:00 [pubmed]
PHST- 2014/05/01 00:01 [medline]
AID - S2212-1099(14)00003-X [pii]
AID - 10.1016/j.vhri.2014.01.002 [doi]
PST - ppublish
SO  - Value Health Reg Issues. 2014 May;3:50-58. doi: 10.1016/j.vhri.2014.01.002. Epub 
      2014 Apr 21.